Teva Pharmaceutical Industries price to sales ratio TEVA

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 2.7×
8-year median: 0.7×
Against its 8-year history: 99th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.4× to 2.8×
Peer median: 7.0×

Teva Pharmaceutical Industries' price to sales ratio is 2.7× as of Oct 23, 2026.

That is above its 8-year median of 0.7×, higher than on 99% of days in the last 8 years.

Over that time it ranged from 0.4× in Aug 2019 to 2.8× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 7.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.7×	1.9×	2.8×
2025	2.2×	0.9×	2.2×
2024	1.5×	0.8×	1.5×
2023	0.8×	0.5×	0.8×
2022	0.7×	0.5×	0.8×
2021	0.5×	0.5×	0.8×
2020	0.6×	0.5×	0.9×
2019	0.6×	0.4×	1.0×
2018	0.8×	0.8×	1.2×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

Company	Price to sales ratio
TEVATeva Pharmaceutical Industries	2.7×
IQVIQVIA	2.7×
MDLNMedline	n/m
WATWaters	9.6×
IDXXIDEXX Laboratories	9.7×
AAgilent Technologies	6.6×
ONCBeOne Medicines	7.0×
HUMHumana	0.3×
EWEdwards Lifesciences	7.9×
ILMNIllumina	9.1×
BDXBecton, Dickinson and	2.6×
Peer median	7.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.